Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury.
Ş, K., S, A., M, B., C, D., S, Y., EM, G., H, B., Y, A., C, T.S., & ÖB, U. (2026). Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury.. Fundamental & clinical pharmacology. https://doi.org/10.1111/fcp.70102
Ş K, S A, M B, C D, S Y, EM G, et al. Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury.. Fundamental & clinical pharmacology. 2026; doi: 10.1111/fcp.70102
Ş K, S A, M B, et al. Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury.[J]. Fundamental & clinical pharmacology. 2026. DOI: 10.1111/fcp.70102.
@article{2026,
author = {Kılıç Ş and Asal S and Babaoğlu M and Demirtaş C and Yavuz S and Güler EM and Beyaztaş H and Aslan Y and Türker Sarıçoban C and Uysal ÖB},
title = {Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury.},
journal = {Fundamental & clinical pharmacology},
year = {2026},
doi = {10.1111/fcp.70102},
note = {PMID: 42363694},
}
TY - JOUR AU - Kılıç Ş AU - Asal S AU - Babaoğlu M AU - Demirtaş C AU - Yavuz S AU - Güler EM AU - Beyaztaş H AU - Aslan Y AU - Türker Sarıçoban C AU - Uysal ÖB TI - Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury. T2 - Fundamental & clinical pharmacology PY - 2026 DO - 10.1111/fcp.70102 AN - PMID:42363694 ER -
PURPOSE: Lower extremity ischemia-reperfusion injury (IRI) triggers systemic inflammation and oxidative stress, causing myocardial remote ischemia-reperfusion injury (MIRI). Current treatments are limited. METHODS: Male Sprague-Dawley rats (n = 6 per group) were assigned to Sham, I/R, I/R + colchicine (C), I/R + HBOT, and I/R + HBOT + C. IRI was induced by 60-min infrarenal aortic clamping and 120-h reperfusion. TREATMENT: Once daily colchicine (0.3 mg/kg) and HBOT (2.5 ATA, 100% O2) twice daily were administered for 5 days post-reperfusion. Cardiac damage, oxidative stress, inflammation, and NRF-2/HO-1 signaling were measured, and electrocardiography (ECG) was performed. RESULTS: I/R caused severe MIRI (Hs-Troponin T: 568.54 pg/mL; heart OSI: 20.98; TNF-α: 582.89 pg/mL). Both monotherapies reduced damage, but HBOT + C was superior: Hs-Troponin T 342.07 pg/mL, OSI 2.26, TNF-α 278.82 pg/mL, and IL-6 12.25 pg/mL, with the upper end of the interquartile range for NRF-2 (41.03) and HO-1 (14.45) activation and restored redox balance (%DIS/NT: 26.31). No differences were observed between groups on the ECG. CONCLUSIONS: Colchicine suppresses inflammation, relieving inhibition of antioxidant defenses, enabling HBOT to fully activate NRF-2/HO-1. This synergistic HBOT + C strategy effectively mitigates MIRI, offering a promising multimodal therapy for remote organ protection after major ischemia.